WO2009132928A3 - Marqueurs moléculaires pour le pronostic d'un cancer - Google Patents
Marqueurs moléculaires pour le pronostic d'un cancer Download PDFInfo
- Publication number
- WO2009132928A3 WO2009132928A3 PCT/EP2009/054034 EP2009054034W WO2009132928A3 WO 2009132928 A3 WO2009132928 A3 WO 2009132928A3 EP 2009054034 W EP2009054034 W EP 2009054034W WO 2009132928 A3 WO2009132928 A3 WO 2009132928A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- high risk
- risk
- low risk
- outcome
- gene expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La présente invention porte sur un procédé d'identification d'un ensemble de gènes donnant des informations sur l'issue d'une maladie qui peuvent être combinées en un algorithme pour un test pronostique ou prédictif. L'algorithme fait usage de données d'expression génique provenant d'échantillons biologiques et définit si les patients ont un risque élevé ou un risque faible, par exemple chez des patients cancéreux, un groupe à issue favorable ou à issue défavorable de métastase. Des profils de référence d'expression génique sont obtenus pour les groupes à risque élevé et à faible risque, respectivement. Un échantillon d'un patient inconnu est analysé et classé comme appartenant au groupe à risque élevé ou à risque faible, respectivement, en fonction de la corrélation avec le profil de référence de risque élevé ou au profil de référence de risque faible.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08008371.0 | 2008-05-02 | ||
| EP08008371 | 2008-05-02 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2009132928A2 WO2009132928A2 (fr) | 2009-11-05 |
| WO2009132928A3 true WO2009132928A3 (fr) | 2009-12-23 |
Family
ID=40875041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2009/054034 Ceased WO2009132928A2 (fr) | 2008-05-02 | 2009-04-03 | Marqueurs moléculaires pour le pronostic d'un cancer |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2009132928A2 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2776751C (fr) * | 2009-11-23 | 2019-07-02 | Genomic Health, Inc. | Procedes destines a predire l'issue clinique d'un cancer |
| FI20105252A0 (fi) | 2010-03-12 | 2010-03-12 | Medisapiens Oy | Menetelmä, järjestely ja tietokoneohjelmatuote biologisen tai lääketieteellisen näytteen analysoimiseen |
| PT2553118E (pt) | 2010-03-31 | 2014-12-17 | Sividon Diagnostics Gmbh | Método para previsão da recorrência de cancro da mama em tratamento endócrino |
| US9777334B2 (en) | 2012-04-30 | 2017-10-03 | The Research Foundation for State University of New York | Cancer blood test using BC200 RNA isolated from peripheral blood for diagnosis and treatment of invasive breast cancer |
| EP2951317B1 (fr) | 2013-02-01 | 2017-10-11 | Sividon Diagnostics GmbH | Procédé pour prédire le bénéfice de l'inclusion de taxane dans un régime de chimiothérapie chez des patients atteints d'un cancer du sein |
| EP3679160A4 (fr) | 2017-09-08 | 2021-05-19 | Myriad Genetics, Inc. | Procédé d'utilisation de biomarqueurs et de variables cliniques pour prédire l'intérêt d'une chimiothérapie |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030158399A1 (en) * | 1995-03-03 | 2003-08-21 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the treatment and diagnosis of immune disorders |
| WO2005033699A2 (fr) * | 2003-10-03 | 2005-04-14 | Ncc Technology Ventures Pte Limited | Dispositifs et methodes destines a la classification du cancer du sein |
| WO2006136314A1 (fr) * | 2005-06-23 | 2006-12-28 | Siemens Medical Solutions Diagnostics Gmbh | Particules magnetiques comportant une couche de silice fermee ultrafine, leur procede de production, et leur utilisation |
| WO2007030611A2 (fr) * | 2005-09-09 | 2007-03-15 | The Board Of Regents Of The University Of Texas System | Indice calcule d'expression genomique de recepteurs des oestrogenes (er) et genes associes aux er |
-
2009
- 2009-04-03 WO PCT/EP2009/054034 patent/WO2009132928A2/fr not_active Ceased
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030158399A1 (en) * | 1995-03-03 | 2003-08-21 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the treatment and diagnosis of immune disorders |
| WO2005033699A2 (fr) * | 2003-10-03 | 2005-04-14 | Ncc Technology Ventures Pte Limited | Dispositifs et methodes destines a la classification du cancer du sein |
| WO2006136314A1 (fr) * | 2005-06-23 | 2006-12-28 | Siemens Medical Solutions Diagnostics Gmbh | Particules magnetiques comportant une couche de silice fermee ultrafine, leur procede de production, et leur utilisation |
| WO2007030611A2 (fr) * | 2005-09-09 | 2007-03-15 | The Board Of Regents Of The University Of Texas System | Indice calcule d'expression genomique de recepteurs des oestrogenes (er) et genes associes aux er |
Non-Patent Citations (3)
| Title |
|---|
| GLINSKY G V ET AL: "Classification of human breast cancer using gene expression profiling as a component of the survival predictor algorithm", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 10, no. 7, 1 April 2004 (2004-04-01), pages 2272 - 2283, XP002309961, ISSN: 1078-0432 * |
| SORLIE T ET AL: "Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 98, no. 19, 11 September 2001 (2001-09-11), pages 10869 - 10874, XP002215483, ISSN: 0027-8424 * |
| VEER VAN 'T L J ET AL: "Gene expression profiling predicts clinical outcome of breast cancer", NATURE, NATURE PUBLISHING GROUP, LONDON, UK, vol. 415, no. 6871, 31 January 2002 (2002-01-31), pages 530 - 536, XP002259781, ISSN: 0028-0836 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009132928A2 (fr) | 2009-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7717608B2 (ja) | メチル化核酸の高深度シーケンシングのための方法とシステム | |
| Dyrskjøt et al. | Identifying distinct classes of bladder carcinoma using microarrays | |
| US9057108B2 (en) | Hybrid model for the classification of carcinoma subtypes | |
| Tsoucas et al. | Recent progress in single-cell cancer genomics | |
| Fan et al. | Methods for genome-wide DNA methylation analysis in human cancer | |
| KR20240018667A (ko) | 메틸롬 분석을 이용한 암 검출 및 분류 | |
| Gnanapragasam | Unlocking the molecular archive: the emerging use of formalin‐fixed paraffin‐embedded tissue for biomarker research in urological cancer | |
| WO2009132928A3 (fr) | Marqueurs moléculaires pour le pronostic d'un cancer | |
| NZ593225A (en) | Gene expression markers (CMYC and Ki-67) for colorectal cancer prognosis | |
| CN110706749A (zh) | 一种基于组织器官分化层次关系的癌症类型预测系统和方法 | |
| WO2008039071A3 (fr) | Essai diagnostique extrêmement productif au moyen de jeux ordonnés | |
| Chung et al. | Gene expression profiling of papillary thyroid carcinomas in Korean patients by oligonucleotide microarrays | |
| CN106868204A (zh) | 一种用于胃腺癌诊断的生物标志物 | |
| CN102782151A (zh) | 作为用于前列腺癌诊断和分期的非侵入性标志物的循环miRNA | |
| CN107729718A (zh) | 一种乳腺癌发生相关特征基因筛选方法 | |
| US20170183738A1 (en) | Process, Apparatus or System and Kit for Classification of Tumor Samples of Unknown and/or Uncertain Origin and Use of Genes of the Group of Biomarkers | |
| WO2008104984A3 (fr) | Diagnostic et pronostic de divers types de cancers | |
| CN111100863B (zh) | 小rna组成的指纹图谱在肺癌的诊断和治疗中的应用 | |
| WO2010046530A8 (fr) | Procédés et utilisations mettant en oeuvre des aberrations génétiques de nav3 et l'expression aberrante de gènes multiples | |
| Michaelson-Cohen et al. | Genome-wide de novo methylation in epithelial ovarian cancer | |
| EP2906713A1 (fr) | Biomarqueurs de microarn pour le cancer de la prostate | |
| WO2020252320A1 (fr) | Caractérisation à haute résolution basée sur la méthylation d'adn de microbiome à l'aide d'un séquençage de nanopores | |
| CN108728439A (zh) | 小rna组成的指纹图谱及其在膀胱癌诊断中的应用 | |
| WO2020089337A1 (fr) | Lecteur à molécule unique pour l'identification de biopolymères | |
| CN109706146A (zh) | 小rna组成的指纹图谱在人的癌性胸腔积液诊断和治疗中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09737972 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 09737972 Country of ref document: EP Kind code of ref document: A2 |